Retatrutide
Body weight, glucose control, visceral fat, and liver fat.
Research Summary
- Evidence
- Strong human trial evidence; investigational
- Primary research
- Human obesity, metabolic, and liver-fat clinical trials.
- Research focus
- Body weight, glucose control, visceral fat, and liver fat.
- Mechanism
- Activates GIP, GLP-1, and glucagon receptors.
- Evidence limits
- A fixed extra calorie-burn allowance and combination use with other incretin drugs are not established by the cited trials.
What retatrutide is
Retatrutide is a long-acting investigational peptide drug that activates GIP, GLP-1 and glucagon receptors. Human trials show unusually large weight loss, improved glucose control, lower visceral abdominal fat and large reductions in liver fat in people with MASLD. It is designed for once-weekly subcutaneous dosing and has a human half-life of about 6 days [1-8].
- Receptors: GIP + GLP-1 + glucagon (GCGR).
- Half-life: about 6 days, which supports weekly dosing.
- Status: Phase 3 investigational, with five positive Phase 3 readouts disclosed by Lilly as of August 2026. Not FDA approved. Lilly has stated a plan to submit a US application (BLA) in Q1 2027; a planned submission is not approval [8].
Who has it been studied in?
The strongest evidence is in adults with obesity or overweight. Trials also include people with type 2 diabetes, severe obesity with cardiovascular disease, obstructive sleep apnea, knee osteoarthritis and MASLD. There is no good evidence that retatrutide should be chosen simply because someone is male or female [6-8,19].
Tirzepatide plus retatrutide has not been tested as a combination. Some people keep tirzepatide for appetite suppression and add retatrutide for a supposed metabolism boost. No controlled human trial has tested this combination. The drugs overlap at GIP and GLP-1 receptors, and the extra calorie burn often used to justify the stack has not been measured in a published human retatrutide calorimetry study [3,10-12,17,18].
Dosing evidence
These are trial exposures. There is no FDA-approved public dosing schedule for retatrutide [1-3,6-8].
Dose at a glance
| Dose | Where it comes from | How to read it |
|---|---|---|
| 2 mg once weekly SC | Phase 3 starting dose | A genuine Phase 3 starting dose. It is not the universal maintenance dose. |
| 4 mg, 9 mg, 12 mg once weekly SC | Main Phase 3 targets | Principal target doses in the initial Phase 3 obesity programme. |
| 6 mg | Phase 3 escalation step | A genuine Phase 3 step on the way to 9 or 12 mg; not one of the principal TRIUMPH-1 targets. |
| 8 mg | Phase 2 target | A genuine Phase 2 target dose. The pivotal Phase 3 programme shifted its main targets to 4, 9 and 12 mg. |
| 0.5 to 1 mg | Phase 2 low doses | Low-dose human exposure exists in Phase 2 [4], but that does not make every community microdose schedule optimised. |
Studied Phase 3 dose path
The clinical programme uses slow escalation so exposure can build and tolerability can be assessed before the next step: 2 mg, then 4 mg, 6 mg, 9 mg and 12 mg, with about four weeks at each step.
| Step | Weekly dose | Time before next increase |
|---|---|---|
| 1 | 2 mg | About 4 weeks |
| 2 | 4 mg | About 4 weeks |
| 3 | 6 mg | About 4 weeks |
| 4 | 9 mg | About 4 weeks |
| 5 | 12 mg | Highest target dose |
- Why waiting matters: retatrutide has a mean half-life of about 6 days. With weekly injections, exposure accumulates over several weeks. A four-week step gives the current dose time to build and gives side effects time to become clear [1,2].
- Why faster escalation is weak logic: not feeling strong appetite suppression in week one does not prove the dose failed. Increasing after only 1 to 2 weeks can add more drug while exposure from the current dose is still building.
The clinical programme supports subcutaneous dosing once weekly, beginning with the studied 2 mg Phase 3 starting dose and allowing about four weeks before the next planned step. That framework fits the roughly 6-day half-life, accumulation and tolerability data.
Community protocols compared with the human research
| Approach | Status | What the evidence shows |
|---|---|---|
| Once weekly | Best supported | The route and frequency used throughout the controlled clinical programme. |
| Twice-weekly split dosing | Plausible, unvalidated | Could smooth peaks and troughs on paper, but no controlled trial shows better efficacy or tolerability. |
| Every 5 to 6 days | Community schedule | Half-life is not an instruction to redose when half remains; the drug was engineered around weekly dosing. |
| 0.25 to 1 mg microdosing | Community strategy | 0.5 and 1 mg have human exposure precedent, but chronic microdosing has not been shown to reproduce Phase 3 outcomes. |
| Escalating after 1 to 2 weeks | Poorly supported | Exposure is still accumulating, so early increases can outrun tolerability assessment. |
Online protocols can look more clinical than they are. Several individual doses used online really did appear somewhere in development. The ladder, interval or split-dosing pattern is then changed from the trial, so the numbers are real while the combined protocol may never have been tested. A real trial dose does not make the surrounding community protocol a clinical protocol: dose, frequency, escalation interval, formulation and treatment goal all need to match the study before its evidence can be transferred.
Do retatrutide, tirzepatide or semaglutide need to be cycled to “rest” the receptors?
No evidence supports it. A plateau or weaker appetite sensation does not prove GLP-1, GIP or glucagon receptors are “burned out.” Some individual effects can adapt over time, including part of the gastric-emptying effect, but there is no human evidence that routine drug holidays prevent receptor damage or make these drugs work better when restarted [22-25].
- Continuous semaglutide remained effective through 104 weeks without a planned receptor-reset cycle [22].
- About two-thirds of prior weight loss was regained within a year after semaglutide withdrawal [23].
- People switched from tirzepatide to placebo in SURMOUNT-4 regained 14.0%, while continued treatment produced another 5.5% reduction [24].
Why “glucagon does not turn on until 4 mg” became common
The claim sounds scientific because 4 mg appears repeatedly in the clinical programme. The evidence does not show a binary receptor switch at that dose. Dose-response is a continuum: retatrutide is the same triple-agonist molecule at every dose, and receptor signalling changes with concentration. Human trials did not measure a point where GCGR is completely inactive and then suddenly switches on.
- Trial doses created landmarks. Phase 2 used 1, 4, 8 and 12 mg, and 4 mg later became the lowest main Phase 3 target.
- Some signals looked clearer at 4 mg and above. That made 4 mg feel biologically special even though receptor occupancy was not measured that way [5].
- A dose anchor became a switch. Community repetition turned “4 mg is an important study dose” into “glucagon is off below 4 mg.”
The trials do not isolate exactly how much of each dose's effect came from GIP, GLP-1 or glucagon, and they do not establish a human receptor-occupancy threshold at 4 mg. 4 mg is a real, effective human trial dose. It is not a demonstrated glucagon activation threshold.
Calorie-burn claims
One of the most widespread claims online is that retatrutide burns a fixed number of extra calories a day. No published human retatrutide study has established a fixed daily calorie-burn bonus. In community discussions, the most common concrete estimate is about 100 to 200 kcal/day, and 150 to 300 also appears. Figures of 400 to 600 kcal/day could not be confirmed as the dominant estimate. None of these numbers comes from published human retatrutide calorimetry [17].
How the claim became convincing
- Glucagon biology. Glucagon can affect energy expenditure and fuel use.
- Retatrutide adds GCGR. It adds glucagon-receptor activity to GIP + GLP-1.
- Weight loss was very large. A hidden metabolism boost became an attractive explanation.
- Exact numbers appeared. A plausible idea turned into precise calorie claims without calorimetry.
What the human evidence says
| Evidence | Finding |
|---|---|
| Retatrutide calorimetry | A completed 85-person Phase 1 study measured 24-hour energy expenditure, sleep metabolic rate, food intake and appetite, but ClinicalTrials.gov still listed no posted results as of 21 August 2026 [21]. |
| Glucagon alone | Mixed. One controlled infusion study found roughly 50 to 70 kcal/day higher measured expenditure [10]; another 72-hour whole-room study found no increase in sleeping, basal or 24-hour expenditure [20]. Neither used retatrutide. |
| Tirzepatide | Human calorimetry found lower food intake and higher fat oxidation, but no increase in 24-hour or sleeping expenditure after accounting for body-composition change [11]. |
| Community estimate | About 100 to 200 kcal/day is the most common figure, with no calorimetry behind it. |
Where walking and daily movement fit. If the only goal is to add roughly 100 to 200 calories of daily expenditure, extra walking, steps or other non-exercise movement can often reach that general range depending on body size and activity. That does not reproduce retatrutide pharmacology. It does show why an unmeasured “metabolism bonus” is a weak reason to stack two overlapping incretin drugs.
Heart rate is not a calorie meter. Retatrutide can raise heart rate, but a faster pulse cannot be converted into a daily calorie-burn number. The human data do not show that the heart-rate increase explains hundreds of extra calories per day [3,10,20].
Body composition evidence
Visceral fat and fatty liver: real human data
These effects were measured with imaging in humans. Retatrutide does reduce visceral fat and liver fat, but the studies do not show selective spot-fat burning or proof of fibrosis reversal [5].
| Measure | Result |
|---|---|
| Visceral abdominal fat reduction, 24 weeks | 13.8% to 31.5% across studied doses |
| Visceral abdominal fat reduction, 48 weeks | 16.1% to 48.3% across studied doses |
| Dose (MASLD substudy, 24 weeks) | Mean relative liver-fat reduction | Reached liver fat under 5% |
|---|---|---|
| 1 mg | 42.9% | 27% |
| 4 mg | 57% | 52% |
| 8 mg | 81.4% | 79% |
| 12 mg | 82.4% | 86% |
- What the study shows: retatrutide substantially reduced MRI-measured liver fat in people with obesity and MASLD, and substantially reduced visceral abdominal fat.
- What it does not show: it did not prove that retatrutide independently “heals” every form of fatty liver disease, reverses fibrosis, or selectively burns visceral fat while sparing subcutaneous fat.
- Why the result makes sense: the liver responds quickly to changes in energy balance, insulin sensitivity and fatty-acid flow. In the substudy, liver-fat reduction tracked strongly with body-weight and abdominal-fat loss, which fits the human data better than the idea that glucagon simply “melts liver fat” on its own.
Does retatrutide preserve more muscle than other GLP-1 drugs?
A common claim is that retatrutide is more muscle-sparing because its glucagon activity shifts more of the weight loss toward fat. Human data do show fat-predominant weight loss. They do not show a unique muscle-preserving effect [9].
The claim sounds logical because most of the loss is fat, so body-fat percentage can fall quickly; because glucagon changes fuel use, which makes “burn more fat, spare muscle” sound plausible even though fuel use is not an anti-catabolic muscle signal; and because less fat, glycogen and water can make someone look smaller or flatter without showing how much contractile muscle changed.
| Body-composition study | Finding |
|---|---|
| Study | 36-week Phase 2 DXA substudy in adults with type 2 diabetes. |
| What changed | Fat mass fell substantially. Lean mass also fell; the study did not show that weight loss was exclusively fat. |
| What the authors concluded | The proportion of lean-mass loss relative to total weight loss was similar to other obesity treatments [9]. |
Glucagon receptor activity changes fuel and amino-acid metabolism. The retatrutide body-composition paper notes a theoretical concern that chronic glucagon signalling could lower circulating amino acids and reduce muscle protein synthesis. The human data were reassuring that lean loss was not disproportionate, but they did not show a special protective effect [9].
| Approach | Lean-mass share of weight lost | Source |
|---|---|---|
| Retatrutide | No proven advantage | Human substudy: lean-mass share was similar to other obesity treatments [9]. |
| Tirzepatide | About 25% | About 75% of weight lost was fat and 25% lean mass in the SURMOUNT-1 DXA substudy [26]. |
| Semaglutide | About 35% (pooled estimate) | A 2026 meta-analysis estimated 35.2% of weight loss was lean mass [27]. |
| Lifestyle plus resistance training | About 18% (pooled estimate) | The same meta-analysis found the lowest lean-mass share when resistance training was included [27]. |
These figures are not a head-to-head ranking. The studies used different populations, durations and methods, and DXA “lean mass” is broader than skeletal muscle: it includes water, glycogen, organs and other non-fat tissue. Retatrutide appears fat-predominant without being uniquely muscle-sparing, and there is no good evidence that choosing it instead of tirzepatide or semaglutide will preserve more skeletal muscle. Resistance training, adequate protein and avoiding an unnecessarily aggressive calorie deficit have a more direct rationale for muscle retention than relying on retatrutide's glucagon activity [27].
Tirzepatide comparison and stacking
What is actually different?
| Topic | Comparison |
|---|---|
| Mechanism | Tirzepatide is an approved dual agonist (GIP + GLP-1). Retatrutide is an investigational triple agonist (GIP + GLP-1 + GCGR). |
| Appetite and food noise | Both reduce food intake. Tirzepatide has mature approved obesity data and a strong real-world appetite-suppression track record. Retatrutide also suppresses appetite, but community reports are more variable. No validated head-to-head food-noise score exists. |
| Energy expenditure | Tirzepatide calorimetry did not show an increase in 24-hour expenditure after accounting for body-composition change. Retatrutide has no published human calorimetry result establishing a fixed calorie-burn amount [11,21]. |
| Visceral and liver fat | Both have human imaging evidence. Retatrutide produced very large liver-fat reductions in a MASLD substudy; tirzepatide also reduced liver fat, VAT and ASAT in SURPASS-3 MRI [5,13]. |
| Current status | Tirzepatide is FDA-approved for obesity and weight management, for OSA in adults with obesity, and for type 2 diabetes under the Mounjaro name. Retatrutide remains investigational [18]. |
| Head-to-head | TRIUMPH-5 directly compares the two in obesity and is scheduled through late 2026. Until it reports, separate-trial percentages are not a direct comparison [14]. |
Separate-trial average weight loss: tirzepatide 15 mg, 20.9% (SURMOUNT-1, 72 weeks); retatrutide 12 mg, 28.3% (TRIUMPH-1, 80 weeks). These are not head-to-head results. The trials used different participants and durations, so subtracting the two and calling retatrutide 7.4% better is not valid [6,12,14].
Which situations favour each drug
| Situation | Leaning | Why |
|---|---|---|
| Need an approved, standardised treatment | Tirzepatide | Established product, dosing, contraindications and monitoring. Retatrutide is still investigational. |
| Type 2 diabetes is a major issue | Tirzepatide | Approved for type 2 diabetes. Retatrutide has strong glucose-lowering trial results but no approval yet. |
| Obesity-related OSA | Tirzepatide | Zepbound is approved for moderate-to-severe OSA in adults with obesity. |
| Obesity plus knee osteoarthritis | Retatrutide signal | Direct Phase 3 evidence for major weight loss plus better knee pain and function; still investigational [19]. |
| Largest average weight loss seen so far | Retatrutide signal | Higher averages in separate trials, but this does not prove superiority before TRIUMPH-5. |
| Food noise is the main problem | No proven winner | Tirzepatide often has strong appetite suppression in practice; retatrutide can also suppress appetite. Anecdotes are not a head-to-head test. |
| High resting heart rate or palpitations | Extra caution | A “metabolism boost” is not a reason to choose retatrutide. A faster pulse is not a useful treatment target. |
If retatrutide is not suppressing appetite enough, adding tirzepatide just to keep retatrutide for a supposed calorie-burn bonus is hard to justify. Tirzepatide already covers GIP + GLP-1 signalling, and the retatrutide calorie bonus has not been demonstrated. Tirzepatide plus regular walking or more daily movement is a different drug effect from retatrutide, but it can address the narrower goal of strong appetite control plus extra activity-related calorie expenditure without stacking two overlapping incretin drugs [11,17,18,21]. The tirzepatide label states that coadministration with another GLP-1 receptor agonist is not recommended [18].
Community stacking claims
Tirzepatide + retatrutide is usually justified as more appetite control plus extra metabolism. Retatrutide + cagrilintide is usually used when hunger or food noise remains a problem. Neither combination has controlled retatrutide outcome data [15,17].
| Stack | Status | What the evidence shows |
|---|---|---|
| Tirzepatide + retatrutide | High overlap | GIP and GLP-1 are duplicated. The popular appetite plus calorie-burn rationale depends heavily on an unmeasured retatrutide metabolism number. |
| Retatrutide + cagrilintide | Less overlap | Adds amylin-based satiety signalling rather than a second GIP/GLP-1 drug. The rationale is clearer when hunger is the problem, but the combination is still untested. |
| More appetite suppression | Not always better | Very strong satiety can make it harder to eat enough protein, fluids and micronutrients and may worsen nausea, constipation or dehydration. |
If the problem is food noise or hunger, it makes more sense to address that directly than to assume a second overlapping incretin is needed to preserve a metabolism bonus that has never been quantified in humans.
Symptoms and safety
Community discussions sometimes treat side effects as receptor biomarkers. Human trials do not validate that approach.
| Dysesthesia in TRIUMPH-4 | Rate |
|---|---|
| Placebo | 0.7% |
| 9 mg | 8.8% |
| 12 mg | 20.9% |
Dysesthesia (abnormal skin sensation) is a safety signal, not a receptor test [19].
| Sign | Status | What it means |
|---|---|---|
| Heart rate | Real signal | Dose-dependent increases occurred in Phase 2. This is a safety and tolerability signal, not proof of calorie burn [3]. |
| Feeling warm | Not a receptor test | Feeling warm has not been validated as a measure of thermogenesis or glucagon-receptor occupancy. |
| Liver enzymes | Not a receptor test | ALT and AST did not change consistently versus placebo in the MASLD substudy; they are not a home test for whether glucagon is “on” [5]. |
What is established about safety
| Effect | Status | Details |
|---|---|---|
| GI effects | Common | Nausea, diarrhoea, vomiting, constipation and decreased appetite, especially during escalation [3,6,7]. |
| Dysesthesia | Repeated signal | Now reproduced in Phase 3; generally mild to moderate but clearly dose-related in TRIUMPH-4 [19]. |
| Heart-rate increase | Real signal | Observed dose-dependently. It is not a desirable metabolism target. |
| Excessive weight loss | Practical risk | Some TRIUMPH-4 discontinuations were associated with perceived excessive weight loss [19]. |
No approved retail retatrutide product exists. Clinical-trial retatrutide uses a controlled investigational formulation. Lilly warns that products sold to consumers outside its trials are not Lilly clinical-trial retatrutide and may contain the wrong ingredient, concentration, impurities or contaminants. There is no approved universal research-vial concentration, reconstitution method, shelf-life rule or public prescribing label [8].
Evidence summary
| Claim | Verdict | Basis |
|---|---|---|
| Obesity efficacy | Very strong | Late-stage human evidence with multiple positive Phase 3 readouts. |
| Fixed extra-calorie claim | Not established | No published retatrutide calorimetry result supports a fixed 100, 200, 400 or 600 kcal/day bonus. |
| Visceral fat | Strong | Direct human imaging evidence for substantial VAT reduction. |
| Liver fat / MASLD | Strong signal | Large human liver-fat reductions; not proof of fibrosis reversal. |
| Muscle preservation | No unique advantage | Human body-composition data do not show a unique muscle-sparing advantage [9]. |
| Cardiovascular outcomes | Not established | Dedicated outcomes research is still needed for firm event-reduction conclusions. |
| Tirzepatide + retatrutide | No combination evidence | High pathway overlap and an unsupported calorie-burn rationale. |
| Retatrutide + cagrilintide | Unvalidated | Less receptor overlap for appetite, but no retatrutide-specific combination trial. |
| 4 mg glucagon threshold | Not established | No human receptor-occupancy study identifies a binary switch at 4 mg. |
| Split dosing / microdosing | Unvalidated | Used in communities, but not compared against once-weekly dosing in controlled outcome trials. |
| Cycling / receptor burnout | No reset evidence | Long-term treatment remained effective; withdrawal studies showed substantial weight regain after stopping [22-24]. |
| Once-weekly SC | Strong | The route and frequency used throughout the clinical programme. |
Conclusion
What is real: retatrutide has unusually strong late-stage human evidence for weight loss, glucose improvement, visceral-fat reduction and liver-fat reduction. Once-weekly subcutaneous dosing with slow titration is the clear clinical-development framework.
What is still overstated: a fixed metabolism bonus, a 4 mg glucagon switch, split-dosing superiority, receptor-reset cycling and untested stacks remain community claims rather than established retatrutide pharmacology.
A real dose number is not a validated protocol, a side effect is not a receptor test, and a plausible mechanism is not a measured clinical effect. The human trials support powerful results, and they also show which online claims add nothing to the evidence.
Sources
- Coskun T, et al. Cell Metabolism (2022). Retatrutide discovery-to-clinical proof of concept; receptor profile, long half-life and once-weekly design.
- Retatrutide Phase 1 pharmacokinetic summaries. Dose-proportional exposure, mean half-life about 6 days and Tmax roughly 12 to 49 hours.
- Jastreboff AM, et al. New England Journal of Medicine (2023). PMID 37366315. Phase 2 obesity trial; dose-response, weight loss, GI tolerability and heart-rate findings.
- Rosenstock J, et al. The Lancet (2023). PMID 37385280. Phase 2 type 2 diabetes trial; supports 0.5 mg and higher weekly human exposures.
- Sanyal AJ, et al. Nature Medicine (2024). PMID 38858523. MASLD substudy; liver fat, visceral fat, subcutaneous abdominal fat, metabolic biomarkers and correlations with weight loss.
- Lilly TRIUMPH-1 / 2026 ADA materials. Phase 3 obesity efficacy; 4, 9 and 12 mg target framework, weight loss and adverse events.
- Bajaj HS, et al. The Lancet (2026). PMID 42250575; Lilly 2026 TRIUMPH updates. Peer-reviewed Phase 3 type 2 diabetes data and latest pivotal readouts.
- Eli Lilly. “What to know about retatrutide,” updated 2026. Investigational status, no legitimate retail product and planned US submission.
- The Lancet Diabetes & Endocrinology (2025), Retatrutide body-composition substudy. Large fat-mass loss with lean-mass proportion similar to other obesity treatments.
- Nair KS, et al. Diabetes (2017), Effects of 13-Hour Hyperglucagonemia on Energy Expenditure. Controlled human glucagon infusion; roughly 50 to 70 kcal/day increase under study conditions.
- Ravussin E, et al. Cell Metabolism (2025). PMID 40203836. Tirzepatide human calorimetry: no increase in adjusted 24-hour expenditure, with increased fat oxidation and lower food intake.
- Jastreboff AM, et al. New England Journal of Medicine (2022). PMID 35658024. SURMOUNT-1; tirzepatide 15 mg mean weight change -20.9% at 72 weeks.
- Gastaldelli A, et al. Lancet Diabetes & Endocrinology (2022). PMID 35468325. SURPASS-3 MRI; tirzepatide reductions in liver fat, VAT and ASAT.
- TRIUMPH-5, NCT06662383 / Lilly trial registry. Direct retatrutide versus tirzepatide comparison in obesity.
- Garvey WT, et al. New England Journal of Medicine (2025). PMID 40544433. CagriSema Phase 3; clinical activity of amylin + GLP-1 coadministration and frequent GI adverse events.
- Pearson MJ, et al. Journal of Clinical Endocrinology & Metabolism (2026). PMID 42135195. Retatrutide metabolomics and lipidomics; fatty-acid oxidation-related signatures and metabolic changes.
- Community sources: Reddit, GLP-1 Forum, PeptideDosages and PeptideFox discussions covering calorie-burn claims, stacking, food-noise strategies, the 4 mg glucagon threshold, microdosing, split dosing, competing dose ladders and receptor-reset claims. Community posts document beliefs and practices; they are not efficacy evidence.
- FDA Zepbound Prescribing Information, revised February 2026. Tirzepatide indications, once-weekly dosing and warning that coadministration with another GLP-1 receptor agonist is not recommended.
- Eli Lilly TRIUMPH-4 Phase 3 results (2025 to 2026 updates). Knee OA pain and weight outcomes; dysesthesia rates and discontinuations including perceived excessive weight loss.
- Whytock KL, et al. Obesity (2021). PMID 34029448. 72-hour glucagon infusion with whole-room calorimetry; no significant increase in sleeping, basal or 24-hour energy expenditure.
- ClinicalTrials.gov NCT06313528 / Lilly J1I-MC-GZBW. Completed 85-person retatrutide study measuring calorie intake, sleep metabolic rate, 24-hour energy expenditure and appetite; no results posted as of 21 August 2026.
- Garvey WT, et al. Nature Medicine (2022). PMID 36216945. STEP 5; continuous semaglutide produced sustained weight loss through 104 weeks without a planned receptor-reset cycle.
- Wilding JPH, et al. Diabetes, Obesity and Metabolism (2022). PMID 35441470. STEP 1 extension; after semaglutide withdrawal, participants regained about two-thirds of prior weight loss within a year.
- Aronne LJ, et al. JAMA (2024). doi:10.1001/jama.2023.24945. SURMOUNT-4; people switched from tirzepatide to placebo regained 14.0%, while continued treatment produced another 5.5% reduction.
- Jalleh RJ, et al. Journal of Clinical Endocrinology & Metabolism (2024). PMID 39418085. Some gastric-emptying effects show tachyphylaxis over prolonged incretin treatment; this is not the same as receptor “burnout.”
- Look M, et al. Diabetes, Obesity and Metabolism (2025). PMID 39996356. SURMOUNT-1 DXA substudy; about 75% of tirzepatide-associated weight loss was fat mass and about 25% lean mass.
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention (2026). PMID 41877354. Meta-analysis: lean mass accounted for about 35.2% of semaglutide weight loss, 25.4% with tirzepatide, 26.2% with lifestyle alone and 17.5% with lifestyle plus resistance training.